{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T13:10:20Z","timestamp":1762434620578,"version":"build-2065373602"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00394-7","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T13:05:29Z","timestamp":1762434329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe"],"prefix":"10.1186","volume":"11","author":[{"given":"Igor","family":"Aurer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Bulj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliya","family":"Demirevska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sini\u0161a","family":"Dragni\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojca","family":"Dreisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veselina","family":"Goranova-Marinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozren","family":"Jak\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luka","family":"Lipar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Rener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branimir","family":"Spassov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Uro\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vojin","family":"Vukovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enisa","family":"\u017dari\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Zdravkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"1","key":"394_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019.","journal-title":"Ann Oncol"},{"issue":"S1","key":"394_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/hon.3145","volume":"41","author":"M Hallek","year":"2023","unstructured":"Hallek M. First line therapy of CLL. Hematol Oncol. 2023;41(S1):129\u201335. https:\/\/doi.org\/10.1002\/hon.3145.","journal-title":"Hematol Oncol"},{"issue":"5","key":"394_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15051583","volume":"15","author":"P Iyer","year":"2023","unstructured":"Iyer P, Wang L. Emerging therapies in CLL in the era of precision medicine. Cancers (Basel). 2023;15(5):1\u201322. https:\/\/doi.org\/10.3390\/cancers15051583.","journal-title":"Cancers (Basel)"},{"key":"394_CR4","doi-asserted-by":"publisher","unstructured":"Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. From biology to therapy: the CLL success story. HemaSphere. 2019;3(2). https:\/\/doi.org\/10.1097\/HS9.0000000000000175.","DOI":"10.1097\/HS9.0000000000000175"},{"issue":"6","key":"394_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/PPO.0000000000000416","volume":"25","author":"TJ Kipps","year":"2019","unstructured":"Kipps TJ, Choi MY. Targeted therapy in chronic lymphocytic leukemia. Cancer J. 2019;25(6):378\u201385. https:\/\/doi.org\/10.1097\/PPO.0000000000000416.","journal-title":"Cancer J"},{"issue":"9","key":"394_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, et al. ESMO clinical practice guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.016.","journal-title":"Ann Oncol"},{"issue":"2","key":"394_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/jha2.888","volume":"5","author":"H Wartmann","year":"2024","unstructured":"Wartmann H, Kabilka A, Deiters B, Schmitz N, Volmer T. A decade of chronic lymphocytic leukaemia therapy in germany: Real-world treatment patterns and outcomes (2010\u20132022). eJHaem. 2024;5(2):346\u201352. https:\/\/doi.org\/10.1002\/jha2.888.","journal-title":"eJHaem"},{"issue":"7","key":"394_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/10428194.2024.2331631","volume":"65","author":"SF Huntington","year":"2024","unstructured":"Huntington SF, Cheng WY, Sarpong EM, et al. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the united states: a longitudinal study. Leuk Lymphoma. 2024;65(7):932\u201342. https:\/\/doi.org\/10.1080\/10428194.2024.2331631.","journal-title":"Leuk Lymphoma"},{"key":"394_CR9","doi-asserted-by":"publisher","unstructured":"Loscertales J, Abrisqueta-Costa P, Gutierrez A, et al. Real-World evidence on the clinical characteristics and management of patients with chronic lymphocytic leukemia in Spain using natural Language processing: the srealcll study. Cancers (Basel). 2023;15(16). https:\/\/doi.org\/10.3390\/cancers15164047.","DOI":"10.3390\/cancers15164047"},{"issue":"1","key":"394_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jha2.322","volume":"3","author":"J Ranti","year":"2022","unstructured":"Ranti J, Perkonoja K, Kauko T, Loponen H, Joensuu EI, J\u00e4rvinen TM. Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center. eJHaem. 2022;3(1):291\u2013300. https:\/\/doi.org\/10.1002\/jha2.322.","journal-title":"eJHaem"},{"issue":"July","key":"394_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/blctt.s326627","volume":"12","author":"F St-Pierre","year":"2022","unstructured":"St-Pierre F, Ma S. Use of BTK inhibitors in chronic lymphocytic Leukemia\/Small lymphocytic lymphoma (CLL\/SLL): A practical guidance. Blood Lymphat Cancer Targets Ther. 2022;12(July):81\u201398. https:\/\/doi.org\/10.2147\/blctt.s326627.","journal-title":"Blood Lymphat Cancer Targets Ther"},{"key":"394_CR12","doi-asserted-by":"publisher","unstructured":"Zhang Q, Wen C, Zhao L, Wang Y. A comprehensive review of Small-Molecule inhibitors Ta Rgeting Bruton tyrosine kinase: synthetic approaches and clinical applications. Molecules. 2023;28(8037). https:\/\/doi.org\/10.3390\/molecules28248037.","DOI":"10.3390\/molecules28248037"},{"issue":"9","key":"394_CR13","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","volume":"8","author":"C Tam","year":"2024","unstructured":"Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8(9):2300\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023012221.","journal-title":"Blood Adv"},{"key":"394_CR14","doi-asserted-by":"publisher","unstructured":"Gordon MJ, Jones JE, George B, et al. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity. Cancer. 2023;January2192\u2013200. https:\/\/doi.org\/10.1002\/cncr.34787.","DOI":"10.1002\/cncr.34787"},{"issue":"3\u20134","key":"394_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00508-019-1534-1","volume":"132","author":"MC St\u00fchlinger","year":"2020","unstructured":"St\u00fchlinger MC, Weltermann A, Staber P, Heintel D, N\u00f6sslinger T, Steurer M. Recommendations for ibrutinib treatment in patients with atrial fibrillation and\/or elevated cardiovascular risk. Wien Klin Wochenschr. 2020;132(3\u20134):97\u2013109. https:\/\/doi.org\/10.1007\/s00508-019-1534-1.","journal-title":"Wien Klin Wochenschr"},{"issue":"25","key":"394_CR16","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJH, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through Inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829\u201330. https:\/\/doi.org\/10.1182\/blood-2014-10-604272.","journal-title":"Blood"},{"issue":"12","key":"394_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life10120344","volume":"10","author":"V Giudice","year":"2020","unstructured":"Giudice V, Vecchione C, Selleri C. Cardiotoxicity of novel targeted hematological therapies. Life. 2020;10(12):1\u201322. https:\/\/doi.org\/10.3390\/life10120344.","journal-title":"Life"},{"issue":"3","key":"394_CR18","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000000986","volume":"144","author":"MG Fradley","year":"2021","unstructured":"Fradley MG, Beckie TM, Brown SA, et al. Recognition, Prevention, and management of arrhythmias and autonomic disorders in Cardio-Oncology: A scientific statement from the American heart association. Circulation. 2021;144(3):e41\u201355. https:\/\/doi.org\/10.1161\/CIR.0000000000000986.","journal-title":"Circulation"},{"key":"394_CR19","doi-asserted-by":"publisher","unstructured":"Barachini S, Buda G, Petrini I. Cardiovascular toxicity of antineoplastic treatments in hematological diseases: focus on molecular mechanisms to improve therapeutic management. J Clin Med. 2024;13(6). https:\/\/doi.org\/10.3390\/jcm13061574.","DOI":"10.3390\/jcm13061574"},{"issue":"12","key":"394_CR20","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/CIRCRESAHA.121.318259","volume":"128","author":"MR Fleming","year":"2021","unstructured":"Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ. Vascular impact of cancer therapies: the case of BTK (Bruton tyrosine Kinase) inhibitors. Circ Res. 2021;128(12):1973\u201387. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318259.","journal-title":"Circ Res"},{"issue":"13","key":"394_CR21","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.056.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"394_CR22","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3324\/haematol.2021.280199","volume":"107","author":"JR Brown","year":"2022","unstructured":"Brown JR, Byrd JC, Ghia P, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022;107(6):1335\u201346. https:\/\/doi.org\/10.3324\/haematol.2021.280199.","journal-title":"Haematologica"},{"issue":"4","key":"394_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/nejmoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332. https:\/\/doi.org\/10.1056\/nejmoa2211582.","journal-title":"N Engl J Med"},{"key":"394_CR24","doi-asserted-by":"publisher","unstructured":"Zhao ZX, Yang TY, Wang YH, Zhang L, Li J, Su YW. Cardiovascular events of bruton\u2019s tyrosine kinase inhibitors: A real-world study based on the united States food and drug administration adverse event reporting system database. Br J Clin Pharmacol. Published online 2024. https:\/\/doi.org\/10.1111\/bcp.16127","DOI":"10.1111\/bcp.16127"},{"issue":"1","key":"394_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.18632\/oncotarget.28589","volume":"15","author":"JN Patel","year":"2024","unstructured":"Patel JN, Singh J, Ghosh N. Bruton\u2019s tyrosine kinase inhibitor-related cardiotoxicity: the quest for predictive biomarkers and improved risk stratification. Oncotarget. 2024;15(1):355\u20139. https:\/\/doi.org\/10.18632\/oncotarget.28589.","journal-title":"Oncotarget"},{"issue":"41","key":"394_CR26","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"7","key":"394_CR27","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","volume":"58","author":"TD Shanafelt","year":"2017","unstructured":"Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630\u20139. https:\/\/doi.org\/10.1080\/10428194.2016.1257795.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"394_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hem3.113","volume":"8","author":"K Stamatopoulos","year":"2024","unstructured":"Stamatopoulos K, Pavlova S, Al-Sawaf O, et al. Realizing precision medicine in chronic lymphocytic leukemia: remaining challenges and potential opportunities. HemaSphere. 2024;8(7):1\u201312. https:\/\/doi.org\/10.1002\/hem3.113.","journal-title":"HemaSphere"},{"issue":"3","key":"394_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/hematolrep15030047","volume":"15","author":"P Nasnas","year":"2023","unstructured":"Nasnas P, Cerchione C, Musuraca G, Martinelli G, Ferrajoli A. How I manage chronic lymphocytic leukemia. Hematol Rep. 2023;15(3):454\u201364. https:\/\/doi.org\/10.3390\/hematolrep15030047.","journal-title":"Hematol Rep"},{"issue":"3","key":"394_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","volume":"4","author":"C Porter","year":"2022","unstructured":"Porter C, Azam TU, Mohananey D, et al. Permissive cardiotoxicity: the clinical crucible of Cardio-Oncology. JACC CardioOncology. 2022;4(3):302\u201312. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.005.","journal-title":"JACC CardioOncology"},{"issue":"4","key":"394_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/bs.acr.2022.03.007","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an international Cardio-Oncology society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399. https:\/\/doi.org\/10.1016\/bs.acr.2022.03.007.","journal-title":"Eur Heart J"},{"key":"394_CR32","doi-asserted-by":"publisher","unstructured":"Gent DG, Dobson R. The 2022 European society of cardiology Cardio-oncology guidelines in focus. Eur Cardiol Rev. 2023;18. https:\/\/doi.org\/10.15420\/ecr.2022.63.","DOI":"10.15420\/ecr.2022.63"},{"issue":"18","key":"394_CR33","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","volume":"6","author":"FT Awan","year":"2022","unstructured":"Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of bruton\u2019s tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6(18):5516\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2022007938.","journal-title":"Blood Adv"},{"key":"394_CR34","doi-asserted-by":"publisher","unstructured":"Anderson MA, Sverdlov AL, Awan FT et al. Australia and new Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with bruton\u2019s tyrosine kinase inhibitors. Intern Med J Published Online 2025:1\u201314. https:\/\/doi.org\/10.1111\/imj.70159","DOI":"10.1111\/imj.70159"},{"issue":"5","key":"394_CR35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","volume":"5","author":"C Quartermaine","year":"2023","unstructured":"Quartermaine C, Ghazi SM, Yasin A, et al. Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology State-of-the-Art review. JACC CardioOncology. 2023;5(5):570\u201390. https:\/\/doi.org\/10.1016\/j.jaccao.2023.09.002.","journal-title":"JACC CardioOncology"},{"issue":"1","key":"394_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bjh.17788","volume":"196","author":"CPS Tang","year":"2022","unstructured":"Tang CPS, Lip GYH, McCormack T, et al. Management of cardiovascular complications of Bruton tyrosine kinase inhibitors. Br J Haematol. 2022;196(1):70\u20138. https:\/\/doi.org\/10.1111\/bjh.17788.","journal-title":"Br J Haematol"},{"key":"394_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf237","author":"D Lenihan","year":"2025","unstructured":"Lenihan D, Bloom M, Copeland-Halperin R, et al. Considerations for the practical management of cardiovascular risk with bruton\u2019s tyrosine kinase inhibitors for patients with CLL. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf237. oyaf237(Published online July 30, 2025.","journal-title":"Oncologist"},{"issue":"1","key":"394_CR38","doi-asserted-by":"publisher","first-page":"190","DOI":"10.20471\/acc.2018.57.01.27","volume":"57","author":"B Jak\u0161i\u0107","year":"2018","unstructured":"Jak\u0161i\u0107 B, Pej\u0161a V, Ostoji\u0107-Koloni\u0107 S, et al. Guidelines for diagnosis and treatment of chronic lymphocytic leukemia. Krohem B-CLL 2017. Acta Clin Croat. 2018;57(1):190\u2013215. https:\/\/doi.org\/10.20471\/acc.2018.57.01.27.","journal-title":"Acta Clin Croat"},{"issue":"2","key":"394_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3325\/cmj.2012.53.115","volume":"53","author":"I Novak","year":"2012","unstructured":"Novak I, Jak\u0161i\u0107 O, Kuli\u0161 T, Batinjan K, Znaor A. Incidence and mortality trends of leukemia and lymphoma in Croatia, 1988\u20132009. Croat Med J. 2012;53(2):115\u201323. https:\/\/doi.org\/10.3325\/cmj.2012.53.115.","journal-title":"Croat Med J"},{"key":"394_CR40","unstructured":"National Health Insurance Fund Bulgaria. Reimbursement list of drugs in oncology and hematology. Published 2024. Accessed October 11. 2024. https:\/\/www.nhif.bg\/bg\/medicine_food\/hospital-drugs\/anti-fatigue"},{"key":"394_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/PHARMACIA.71.E126016","volume":"71","author":"V Goranova-Marinova","year":"2024","unstructured":"Goranova-Marinova V, Grekova-Kafalova D, Andreevska K, et al. Analysis of the Pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a single hematology center in Plovdiv, Bulgaria. Pharmacia. 2024;71:1\u201319. https:\/\/doi.org\/10.3897\/PHARMACIA.71.E126016.","journal-title":"Pharmacia"},{"key":"394_CR42","unstructured":"National Council of Prices and Reimbursement of the Medical Drugs in Bulgaria. Pharmacotherapeutic Guidelines for Hematology. Published 2024. Accessed October 11. 2024. Priturka_Naredba_za_izmenenie_na_FTR_po_klinichna_hematologiya.pdf."},{"issue":"11","key":"394_CR43","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology study group of the heart failure association of the European society. Eur J Heart Fail. 2020;22(11):1945\u201360. https:\/\/doi.org\/10.1002\/ejhf.1920.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"394_CR44","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.33963\/v.kp.96840","volume":"81","author":"P Leszek","year":"2023","unstructured":"Leszek P, Klotzka A, Bartu\u015b S, et al. A practical approach to the 2022 ESC cardio-oncology guidelines: comments by a team of experts \u2013 cardiologists and oncologists. Kardiol Pol. 2023;81(10):1047\u201363. https:\/\/doi.org\/10.33963\/v.kp.96840.","journal-title":"Kardiol Pol"},{"issue":"34","key":"394_CR45","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"F Visseren","year":"2021","unstructured":"Visseren F, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"key":"394_CR46","unstructured":"Poku N, Ramalingam S, Andres MS, Gevaert S, Lyon AR. Monitoring and treatment of cardiovascular complications during cancer therapies. Part I: Anthracyclines, HER2-targeted therapies and fluoropyrimidines. European Society of Cardiology, Council for Cardiology Practice. Published. 2023. https:\/\/www.escardio.org\/Councils\/Council-for-Cardiology-Practice-(CCP)\/Cardiopractice\/monitoring-and-treatment-of-cardiovascular-complications-during-cancer-therapies-Part-2"},{"issue":"6","key":"394_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.rec.2022.12.004","volume":"76","author":"SEC Working Group for the 2022 ESC guidelines on cardio-oncology and SEC Guidelines Committee","year":"2023","unstructured":"SEC Working Group for the 2022 ESC guidelines on cardio-oncology and SEC Guidelines Committee. Comments on the 2022 ESC guidelines on cardio-oncology. Rev Esp Cardiol (Engl Ed). 2023;76(6):409\u201316. https:\/\/doi.org\/10.1016\/j.rec.2022.12.004.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"36","key":"394_CR48","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"3","key":"394_CR49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaccao.2022.12.008","volume":"5","author":"D Farmakis","year":"2023","unstructured":"Farmakis D, Papingiotis G, Filippatos G. Genetic predisposition to cardiovascular disease in patients with cancer: A clinical perspective. JACC CardioOncology. 2023;5(3):402\u20135. https:\/\/doi.org\/10.1016\/j.jaccao.2022.12.008.","journal-title":"JACC CardioOncology"},{"issue":"1","key":"394_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-024-00237-x","volume":"10","author":"S Vallabhaneni","year":"2024","unstructured":"Vallabhaneni S, Adusumalli S, Wu J, Groeneveld PW, Gerson J, O\u2019Quinn RP. Cardiotoxicity from Bruton tyrosine kinase inhibitors (BTKi)\u2014an analysis of an administrative health claims database. Cardio-Oncology. 2024;10(1):1\u20138. https:\/\/doi.org\/10.1186\/s40959-024-00237-x.","journal-title":"Cardio-Oncology"},{"issue":"33","key":"394_CR51","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"issue":"5","key":"394_CR52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Kirchhof P, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"40","key":"394_CR53","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997\u20134126. https:\/\/doi.org\/10.1093\/eurheartj\/ehac262.","journal-title":"Eur Heart J"},{"issue":"21","key":"394_CR54","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","volume":"77","author":"VU Rao","year":"2021","unstructured":"Rao VU, Reeves DJ, Chugh AR, et al. Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC State-of-the-Art review. J Am Coll Cardiol. 2021;77(21):2693\u2013716. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.009.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"394_CR55","first-page":"29","volume":"13","author":"E Malangone-Monaco","year":"2023","unstructured":"Malangone-Monaco E, Ryan K, Marchlewicz EH, Lo J, Huntington S. Economic burden of cardiovascular events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the first year after initiating treatment with a novel agent. J Hematol Oncol Pharm. 2023;13(1):29\u201338.","journal-title":"J Hematol Oncol Pharm"},{"issue":"4","key":"394_CR56","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/bjh.16859","volume":"190","author":"K Larsson","year":"2020","unstructured":"Larsson K, Mattsson M, Ebrahim F, Glimelius I, H\u00f6glund M. High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study. Br J Haematol. 2020;190(4):e245\u20138. https:\/\/doi.org\/10.1111\/bjh.16859.","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"394_CR57","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2023-174560","volume":"142","author":"MJ Fernandez Turizo","year":"2023","unstructured":"Fernandez Turizo MJ, Kim E, Asnani A, Yankama T, Von Keudell G, Mej\u00edas-De Jes\u00fas C. Pre-Existing cardiovascular disease increases the risk of cardiovascular adverse events during Bruton tyrosine kinase inhibitor therapy. Blood. 2023;142(Supplement 1):496\u2013496. https:\/\/doi.org\/10.1182\/blood-2023-174560.","journal-title":"Blood"},{"key":"394_CR58","doi-asserted-by":"publisher","unstructured":"Ghous G, Gvazava N, Egwom P, Saleh M, Franco D. Poster session NGS analysis of germline mutation profile of patients with hepatocellular carcinoma in. Published Online. 2023;10585. https:\/\/doi.org\/10.1200\/JCO.2022.40.16.","DOI":"10.1200\/JCO.2022.40.16"},{"issue":"1","key":"394_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-021-00125-8","volume":"7","author":"JC Avalon","year":"2021","unstructured":"Avalon JC, Fuqua J, Miller T, et al. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with ibrutinib. Cardio-Oncology. 2021;7(1):1\u20138. https:\/\/doi.org\/10.1186\/s40959-021-00125-8.","journal-title":"Cardio-Oncology"},{"issue":"1","key":"394_CR60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jha2.638","volume":"4","author":"A Mato","year":"2023","unstructured":"Mato A, Tang B, Azmi S, et al. A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first\u2010line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the united States. eJHaem. 2023;4(1):135\u201344. https:\/\/doi.org\/10.1002\/jha2.638.","journal-title":"eJHaem"},{"key":"394_CR61","doi-asserted-by":"publisher","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9(March). https:\/\/doi.org\/10.3389\/fcell.2021.630942.","DOI":"10.3389\/fcell.2021.630942"},{"issue":"17","key":"394_CR62","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1200\/JCO.23.02738","volume":"42","author":"PL Fedele","year":"2024","unstructured":"Fedele PL, Opat S. Chronic lymphocytic leukemia: time to care for the survivors. J Clin Oncol. 2024;42(17):2005\u201311. https:\/\/doi.org\/10.1200\/JCO.23.02738.","journal-title":"J Clin Oncol"},{"issue":"4","key":"394_CR63","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.3390\/curroncol30040322","volume":"30","author":"S Nixon","year":"2023","unstructured":"Nixon S, Duquette D, Doucette S, Larouche JF. How we manage patients with indolent B-Cell malignancies on bruton\u2019s tyrosine kinase inhibitors: practical considerations for nurses and pharmacists. Curr Oncol. 2023;30(4):4222\u201345. https:\/\/doi.org\/10.3390\/curroncol30040322.","journal-title":"Curr Oncol"},{"key":"394_CR64","unstructured":"European Medicines Agency. ibrutinib EPAR - Product information. Published 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imbruvica"},{"key":"394_CR65","unstructured":"European Medicines Agency. acalabrutinib EPAR - Product information. Published 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/calquence-epar-product-information_en.pdf"},{"key":"394_CR66","unstructured":"European Medicines Agency. Zanubrutinib EPAR - Product information. Published online 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/brukinsa"},{"issue":"7","key":"394_CR67","doi-asserted-by":"publisher","first-page":"527","DOI":"10.18553\/jmcp.2012.18.7.527","volume":"18","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527\u201339. https:\/\/doi.org\/10.18553\/jmcp.2012.18.7.527.","journal-title":"J Manag Care Pharm"},{"issue":"Cvd","key":"394_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.34134","volume":"15","author":"RA Memon","year":"2023","unstructured":"Memon RA, Raveena Bai B, Simran F, et al. Effect of the polypill on adherence and prevention of cardiovascular diseases in patients with or at high risk of cardiovascular diseases: A Meta-Analysis of randomized controlled trials. Cureus. 2023;15(Cvd):1\u20138. https:\/\/doi.org\/10.7759\/cureus.34134.","journal-title":"Cureus"},{"key":"394_CR69","doi-asserted-by":"publisher","unstructured":"Sadeghi M, Askari A, Bostan F, et al. Medication adherence with polypill in cardiovascular disease and High-Risk patients: A systematic review and Meta-Analysis of randomized controlled trials involving 7364 participants. Curr Probl Cardiol. 2024;49(1). https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102061.","DOI":"10.1016\/j.cpcardiol.2023.102061"},{"issue":"3","key":"394_CR70","doi-asserted-by":"publisher","first-page":"100608","DOI":"10.1016\/j.jscai.2023.100608","volume":"2","author":"A Mendez-Ruiz","year":"2023","unstructured":"Mendez-Ruiz A, Lossos IS, Cohen MG. Bleeding risk with antiplatelets and bruton\u2019s tyrosine kinase inhibitors in patients with percutaneous coronary intervention. J Soc Cardiovasc Angiogr Interv. 2023;2(3):100608. https:\/\/doi.org\/10.1016\/j.jscai.2023.100608.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"March","key":"394_CR71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.thromres.2019.04.024","volume":"179","author":"M Bhatti","year":"2019","unstructured":"Bhatti M, Ayton S, Michail O, et al. Effect of bruton\u2019s tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction. Thromb Res. 2019;179(March):64\u20138. https:\/\/doi.org\/10.1016\/j.thromres.2019.04.024.","journal-title":"Thromb Res"},{"issue":"1","key":"394_CR72","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/HEMATOLOGY.2020000118","volume":"20","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol (United States). 2020;20(1):336\u201345. https:\/\/doi.org\/10.1182\/HEMATOLOGY.2020000118.","journal-title":"Hematol (United States)"},{"issue":"24","key":"394_CR73","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1182\/blood-2017-09-808808","volume":"131","author":"K Busygina","year":"2018","unstructured":"Busygina K, Jamasbi J, Seiler T, et al. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. Blood. 2018;131(24):2605\u201316. https:\/\/doi.org\/10.1182\/blood-2017-09-808808.","journal-title":"Blood"},{"key":"394_CR74","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/cancers.17142302","volume":"17","author":"I Mandac Smoljanovi\u0107","year":"2025","unstructured":"Aurer I. Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem. Leuk Lymphoma. 2023;64(sup1):S1\u2013197. https:\/\/doi.org\/10.3390\/cancers.17142302","journal-title":"Cancers"},{"key":"394_CR75","unstructured":"Slavcheva V, Graklanov V, Radinoff A et al. Real-world disease characteristics and first-line therapy in patients with chronic lymphocytic leukemia in bulgaria: the DESCRIBE study (interim analysis) abstract PB2558. EHA Libr. 2024;421324. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/421324\/vanya.slavcheva.real-world.disease.characteristics.and.first-line.therapy.in.html"},{"key":"394_CR76","doi-asserted-by":"publisher","unstructured":"Gambril JA, Ghazi SM, Sansoterra S, et al. Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation. Leukemia 2024;(December. 2023;1\u20139. https:\/\/doi.org\/10.1038\/s41375-024-02334-3.","DOI":"10.1038\/s41375-024-02334-3"},{"issue":"1","key":"394_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-022-08023-0","volume":"22","author":"L Ljungholm","year":"2022","unstructured":"Ljungholm L, Edin-Liljegren A, Ekstedt M, Klinga C. What is needed for continuity of care and how can we achieve it? \u2013 Perceptions among multiprofessionals on the chronic care trajectory. BMC Health Serv Res. 2022;22(1):1\u201315. https:\/\/doi.org\/10.1186\/s12913-022-08023-0.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"394_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2105\/AJPH.2011.300640","volume":"102","author":"JD D\u2019Amore","year":"2012","unstructured":"D\u2019Amore JD, Sittig DF, Ness RB. How the continuity of care document can advance medical research and public health. Am J Public Health. 2012;102(5):1\u20134. https:\/\/doi.org\/10.2105\/AJPH.2011.300640.","journal-title":"Am J Public Health"},{"issue":"1","key":"394_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/835356","volume":"2012","author":"S Testa","year":"2012","unstructured":"Testa S, Paoletti O, Zimmermann A, Bassi L, Zambelli S, Cancellieri E. The role of anticoagulation clinics in the era of new oral anticoagulants. Thrombosis. 2012;2012(1):1\u20136. https:\/\/doi.org\/10.1155\/2012\/835356.","journal-title":"Thrombosis"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00394-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T13:05:34Z","timestamp":1762434334000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00394-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00394-7","relation":{},"ISSN":["2057-3804"],"issn-type":[{"type":"electronic","value":"2057-3804"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper is an expert opinion\/review. The ethic approval was not applicable (no human research involved).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Igor Aurer has the following financial relationships to disclose: AbbVie, AstraZeneca, Beigene\/Swixx, Caribou Biosciences, Eli Lilly, Genesis\/Incyte, Johnson & Johnson, Novartis\/Sandoz, Roche, Sobi, and Takeda. Nikola Bulj has the following financial relationships to disclose: AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Krka, Novartis\/Sandoz, Pfizer, Stada, and Swixx. Liliya Demirevska has received consult honoraria from AstraZeneca, and Berlin Chemie. Sini\u0161a Dragni\u0107 has the following financial relationships to disclose: AstraZeneca, Boehringer Ingelheim, Medtronic, Novartis, and Novo Nordisk. Mojca Dreisinger has received a speaker honoraria from AstraZeneca, AbbVie, Bristol Myers Squibb, Johnson & Johnson, Novartis and Sobi. Veselina Goranova-Marinova has the following financial relationships to disclose: Amgen, AbbVie, Johnson & Johnson, Pfizer, Swixx, and Takeda. Ozren Jak\u0161i\u0107 has the following financial relationships to disclose: AbbVie, AstraZeneca, Beigene\/Swixx, Caribou Biosciences, Eli Lilly, Genesis\/Incyte, Johnson & Johnson, Novartis\/Sandoz, and Roche. Luka Lipar has received consult honoraria from Abbot, Amgen, AOP, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Chiesi, Johnson & Johnson, Krka, Lek, Novartis, Servier, and Swixx. Karla Rener has received consult honoraria from AstraZeneca, Bayer, Johnson & Johnson, Novo Nordisk, Novartis, Pfizer, Roche, Sobi, and Takeda. Branimir Spassov has received a speaker honoraria from: AbbVie, Astellas, and Novartis. Ivana Uro\u0161evi\u0107 has the following financial relationships to disclose: AstraZeneca, Johnson & Johnson, Novartis\/Sandoz, Roche, and Takeda. Vojin Vukovic has received speaker honoraria from Amicus, Medica Linea, Roche, and travel support from Takeda. Enisa \u017dari\u0107 has the following direct financial relationships to disclose: Amicus, AstraZeneca, Johnson & Johnson, Roche, Novartis, Pharmaswiss, and Takeda. Marija Zdravkovi\u0107 has the following financial relationships to disclose: invited lecturer for Novartis, Medtronic, and Stada group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}